{"denoms":[{"counts":[{"groupId":"BG000","value":"166"},{"groupId":"BG001","value":"166"},{"groupId":"BG002","value":"332"}],"units":"Participants"}],"groups":[{"description":"Patients receive oral thalidomide daily and oral prednisone every other day for 4 years in the absence of disease progression or unacceptable toxicity.\n\nprednisone: Given orally\n\nthalidomide: Given orally","id":"BG000","title":"Prednisone"},{"description":"Patients undergo observation.","id":"BG001","title":"Observation"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"102"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"205"}]}],"title":"Age < 60"},{"categories":[{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"127"}]}],"title":"Age > or = 60"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"114"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"110"},{"groupId":"BG002","value":"218"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"162"},{"groupId":"BG001","value":"162"},{"groupId":"BG002","value":"324"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"8"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}